Home > Press > Bioalliance Pharma Announces Its Participation in the Natixis Securities Midcap Healthcare Conference
BioAlliance Pharma SA (Paris:BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics which address resistance issues in cancer, HIV and opportunistic infections, today announced that it will take part in an international business conference devoted to meetings between institutional investors and healthcare/biotech companies:
* The Natixis Securities MidCap Healthcare Conference, November 16, Paris.
(at Salons France Amériques, 9-11 Avenue Franklin Roosevelt)
Dominique Costantini, BioAlliance Pharma's President and CEO, will present the company to institutional investors in plenary session #1 at 9.45am on Friday, November 16.
Bioalliance Pharma Announces Its Participation in the Natixis Securities Midcap Healthcare Conference
PARIS, France | Posted on November 12th, 2007
BioAlliance is the first French high-growth company to have developed a product on the basis of innovative academic research results and to have completed the drug development process all the way up to and including market launch. With a broad and diversified portfolio of innovative products (including three in Phase III trials and a number of promising preclinical programs in cancer and HIV), the company has highlighted its determination to achieve growth throughout Europe.
About BioAlliance Pharma SA
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance. The company is currently developing three innovative clinical-phase products based on the Lauriad® muco-adhesive technology (which enables early, prolonged release of therapeutic agents at the site of the disease; one product is already on the market in France and two phase III clinical trials are ongoing - Loramyc® and acyclovir Lauriad®) and the Transdrug® nanoparticle technology (designed specifically for intracellular targeting of resistant cells: a pivotal phase III primary liver cancer trial is underway with doxorubicin Transdrug®). The company is also developing a new therapeutic entities program focused on the oncology and HIV market.
In 2007, the company established two strategic partnerships to sell its first product (Loramyc®) in the USA and Europe (where the French market launch was announced in September 2007).
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which is available on the AMF website ( http://www.amf-france.org ) or on BioAlliance Pharma S.A.'s website ( http://www.bioalliancepharma.com ).
For press releases and other company information, visit http://www.bioalliancepharma.com .
For more information, please click here
BioAlliance Pharma SA
President and CEO
Tel.: +33 1 45 58 76 01
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Interactive Printed Products – New Applications Enabled by Organic and Printed Electronics May 16th, 2013
Nanometrics Announces Upcoming Investor Events May 14th, 2013
INSCX™ exchange to present a nanotechnology-based Emission Reduction Programme, Ankara, Turkey, June 2013 May 14th, 2013
VDMA: New “Photonics Industry Report 2013” presented May 14th, 2013